AstraZeneca to showcase latest research on comprehensive portfolio and pipeline aimed at transforming respiratory diseases at ATS 2025: Cambridge, UK Wednesday, May 14, 2025, 13:0 ...

In the domestic brewery segment, increased sales contribution from the beer category should help drive margin improvement. Kirin has increased its marketing investments for Harekaze and Hyoketsu, ...

The chronic pruritus market is expected to grow across the 7MM, driven by the introduction of innovative therapies like ...

Commerce officials approved an incentives package worth up to $13.1 million for the company, which plans to build a $700 million plant in the Wake County town. It's the latest drugmaker to target the ...

North Carolina officials are expected to announce another major corporate deal as early as Monday — one that could bring an ...

Improvements in Scalp Itch-Numeric Rating Scale (SI-NRS) were greater in the roflumilast group than for the vehicle group, ...

Afatinib has broad activity against EGFR mutations. However, the approval for uncommon mutations was based on data from 38 ...

Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

James Bradner; Executive Vice President, Research and Development, and Chief Scientific Officer; Amgen Inc Peter Griffith; Executive Vice President and Chief Financial Officer; Amgen Inc Good ...

(RTTNews) - Amgen Inc. (AMGN) announced that it swung to profit in its first quarter of 2025 from a loss last year, helped by higher revenues and an unrealized gain on its BeiGene, Ltd. equity ...

Biosimilar Portfolio Sales: $735 million, a 35% increase year over year. Global Product Sales Growth: 14% in the US. Amgen Inc (NASDAQ:AMGN) reported a 9% year-over-year revenue growth, with a 14% ...

Submission of New Drug Application for ziftomenib to FDA - Kura and Kyowa Kirin Co., Ltd. (Kyowa Kirin) announced submission of the New Drug Application (NDA) for ziftomenib for the treatment of adult ...